AV Homes Inc (AVHI)
Stock chart
Loading...
•
Purchase
•
Sale
•
Planned purchase
•
Planned sale
Net purchase
Net sale
Earnings
Earnings
Value bought
Past 90 days
Value sold
Past 90 days
Net insiders buying
Past 90 days
Trades (buy and sell)
Past 90 days
Search
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
| Notification date | Transaction date | B/S Transaction type | Insider and/or position |
Nb. shares Price Value |
Number of shares | Price | Value | Details |
|---|---|---|---|---|---|---|---|---|
| 2025-02-28 | 2025-02-27 | S Sale |
EVP Sales, Customer Excellence Officer |
774
-0.9%
17.00USD 13,158 |
774 -0.9% | 17.00 | USD 13,158 | |
| 2025-02-28 | 2025-02-27 | S Sale |
SVP & Chief Accounting Officer Officer |
1,033
-2.5%
17.00USD 17,561 |
1,033 -2.5% | 17.00 | USD 17,561 | |
| 2025-02-28 | 2025-02-26 | S Sale |
EVP Sales, Customer Excellence Officer |
3,758
-4.1%
17.53USD 65,878 |
3,758 -4.1% | 17.53 | USD 65,878 | |
| 2025-02-28 | 2025-02-26 | S Sale |
SVP & Chief Accounting Officer Officer |
4,907
-10.8%
17.53USD 86,020 |
4,907 -10.8% | 17.53 | USD 86,020 | |
| 2024-09-06 | 2024-09-05 | S Sale |
SVP & Chief Accounting Officer Officer |
3,525
-10.7%
25.06USD 88,337 |
3,525 -10.7% | 25.06 | USD 88,337 | |
| 2024-08-01 | 2024-07-31 | S Sale |
EVP, AMEA Officer |
100
-0.1%
28.00USD 2,800 |
100 -0.1% | 28.00 | USD 2,800 | |
| 2024-08-01 | 2024-07-30 | PS Planned sale |
EVP, AMEA Officer |
10,000
-11.9%
27.00USD 270,000 |
10,000 -11.9% | 27.00 | USD 270,000 | |
| 2024-03-12 | 2024-03-08 | PS Planned sale |
SVP & Chief Accounting Officer Officer |
3,685
-9.7%
25.63USD 94,447 |
3,685 -9.7% | 25.63 | USD 94,447 | |
| 2024-03-01 | 2024-02-29 | S Sale |
EVP, AMEA Officer |
13,074
-13.5%
24.53USD 320,705 |
13,074 -13.5% | 24.53 | USD 320,705 | |
| 2024-03-01 | 2024-02-29 | S Sale |
EVP Sales, Customer Excellence Officer |
4,910
-4.9%
24.52USD 120,393 |
4,910 -4.9% | 24.52 | USD 120,393 | |
| 2024-02-27 | 2024-02-27 | S Sale |
EVP Sales, Customer Excellence Officer |
6,203
-5.8%
24.49USD 151,911 |
6,203 -5.8% | 24.49 | USD 151,911 | |
| 2023-09-07 | 2023-09-07 | S Sale |
SVP & Chief Accounting Officer Officer |
7,577
-21.2%
20.64USD 156,389 |
7,577 -21.2% | 20.64 | USD 156,389 | |
| 2023-08-28 | 2023-08-25 | S Sale |
EVP, Americas and Europe Officer |
25,000
-13.5%
21.47USD 536,750 |
25,000 -13.5% | 21.47 | USD 536,750 | |
| 2023-04-13 | 2023-04-11 | S Sale |
EVP, AMEA Officer |
1,498
-1.5%
21.18USD 31,728 |
1,498 -1.5% | 21.18 | USD 31,728 | |
| 2023-03-06 | 2023-03-03 | PS Planned sale |
EVP, Biopharma Production Officer |
3,914
-3.5%
25.00USD 97,850 |
3,914 -3.5% | 25.00 | USD 97,850 | |
| 2023-03-01 | 2023-02-28 | PS Planned sale |
EVP, AMEA Officer |
2,324
-2.3%
24.32USD 56,520 |
2,324 -2.3% | 24.32 | USD 56,520 | |
| 2023-03-01 | 2023-02-27 | PS Planned sale |
EVP, Biopharma Production Officer |
3,059
-2.6%
25.00USD 76,475 |
3,059 -2.6% | 25.00 | USD 76,475 | |
| 2023-02-27 | 2023-02-23 | PS Planned sale |
EVP, AMEA Officer |
3,078
-3.2%
24.24USD 74,611 |
3,078 -3.2% | 24.24 | USD 74,611 | |
| 2023-02-22 | 2023-02-22 | PS Planned sale |
EVP, AMEA Officer |
19,160
-16.5%
24.12USD 462,139 |
19,160 -16.5% | 24.12 | USD 462,139 | |
| 2023-02-02 | 2023-02-02 | PS Planned sale |
EVP, Biopharma Production Officer |
11,339
-10.0%
25.06USD 284,155 |
11,339 -10.0% | 25.06 | USD 284,155 | |
| 2022-11-17 | 2022-11-16 | B Purchase |
EVP & CFO Officer |
12,500
+54.0%
20.71USD 258,850 |
12,500 +54.0% | 20.71 | USD 258,850 | |
| 2022-11-17 | 2022-11-16 | B Purchase |
CEO Executive Director |
15,000
+3.6%
20.95USD 314,250 |
15,000 +3.6% | 20.95 | USD 314,250 | |
| 2022-05-23 | 2022-05-23 | S Sale |
EVP, Americas & Europe Officer |
39,000
-23.5%
31.61USD 1,232,790 |
39,000 -23.5% | 31.61 | USD 1,232,790 | |
| 2022-05-23 | 2022-05-20 | PS Planned sale |
EVP, Biopharma Production Officer |
19,603
-16.8%
31.27USD 612,986 |
19,603 -16.8% | 31.27 | USD 612,986 | |
| 2022-03-02 | 2022-03-01 | PS Planned sale |
EVP, Biopharma Production Officer |
2,027
-1.5%
34.47USD 69,871 |
2,027 -1.5% | 34.47 | USD 69,871 | |
| 2022-02-25 | 2022-02-23 | PS Planned sale |
EVP, Biopharma Production Officer |
3,059
-2.4%
33.79USD 103,364 |
3,059 -2.4% | 33.79 | USD 103,364 | |
| 2022-01-05 | 2022-01-05 | PS Planned sale |
EVP, Biopharma Production Officer |
11,551
-8.1%
38.65USD 446,446 |
11,551 -8.1% | 38.65 | USD 446,446 | |
| 2022-01-05 | 2022-01-03 | PS Planned sale |
EVP, Biopharma Production Officer |
59,418
-29.4%
40.77USD 2,422,472 |
59,418 -29.4% | 40.77 | USD 2,422,472 | |
| 2021-12-23 | 2021-12-22 | PS Planned sale |
EVP, AMEA Officer |
28,125
-20.3%
41.53USD 1,168,031 |
28,125 -20.3% | 41.53 | USD 1,168,031 | |
| 2021-12-23 | 2021-12-21 | PS Planned sale |
EVP, AMEA Officer |
38,309
-25.7%
41.00USD 1,570,669 |
38,309 -25.7% | 41.00 | USD 1,570,669 | |
| 2021-12-10 | 2021-12-09 | PS Planned sale |
EVP, AMEA Officer |
7,859
-6.6%
40.24USD 316,246 |
7,859 -6.6% | 40.24 | USD 316,246 | |
| 2021-12-10 | 2021-12-08 | PS Planned sale |
EVP, AMEA Officer |
5,828
-5.0%
40.00USD 233,120 |
5,828 -5.0% | 40.00 | USD 233,120 | |
| 2021-12-03 | 2021-12-01 | PS Planned sale | Non-Executive Director |
100,000
-10.2%
39.30USD 3,930,000 |
100,000 -10.2% | 39.30 | USD 3,930,000 | |
| 2021-11-15 | 2021-11-12 | S Sale |
EVP, Europe Officer |
80,000
-34.1%
38.25USD 3,060,000 |
80,000 -34.1% | 38.25 | USD 3,060,000 | |
| 2021-11-15 | 2021-11-11 | PS Planned sale |
EVP, Europe Officer |
60,804
-28.2%
38.41USD 2,335,482 |
60,804 -28.2% | 38.41 | USD 2,335,482 | |
| 2021-11-02 | 2021-11-01 | PS Planned sale | Non-Executive Director |
100,000
-9.3%
40.31USD 4,031,000 |
100,000 -9.3% | 40.31 | USD 4,031,000 | |
| 2021-10-04 | 2021-10-01 | PS Planned sale | Non-Executive Director |
100,000
-8.5%
39.94USD 3,994,000 |
100,000 -8.5% | 39.94 | USD 3,994,000 | |
| 2021-09-02 | 2021-09-01 | PS Planned sale | Non-Executive Director |
100,000
-7.8%
39.45USD 3,945,000 |
100,000 -7.8% | 39.45 | USD 3,945,000 | |
| 2021-07-13 | 2021-07-09 | PS Planned sale |
EVP, Strategic Partners Officer |
12,221
-12.4%
35.64USD 435,556 |
12,221 -12.4% | 35.64 | USD 435,556 | |
| 2021-07-13 | 2021-07-09 | PS Planned sale |
EVP, Strategic Partners Officer |
6,110
-5.9%
35.56USD 217,272 |
6,110 -5.9% | 35.56 | USD 217,272 | |
| 2021-06-29 | 2021-06-28 | PS Planned sale |
EVP, AMEA Officer |
28,096
-20.3%
35.73USD 1,003,870 |
28,096 -20.3% | 35.73 | USD 1,003,870 | |
| 2021-06-28 | 2021-06-25 | PS Planned sale | Non-Executive Director |
68,605
-4.7%
35.32USD 2,423,129 |
68,605 -4.7% | 35.32 | USD 2,423,129 | |
| 2021-06-10 | 2021-06-10 | PS Planned sale |
President and CEO Executive Director |
57,375
-3.9%
32.48USD 1,863,540 |
57,375 -3.9% | 32.48 | USD 1,863,540 | |
| 2021-06-10 | 2021-06-10 | PS Planned sale |
President and CEO Executive Director |
42,512
-2.9%
32.48USD 1,380,790 |
42,512 -2.9% | 32.48 | USD 1,380,790 | |
| 2021-06-10 | 2021-06-09 | PS Planned sale |
President and CEO Executive Director |
235,170
-14.4%
32.03USD 7,532,495 |
235,170 -14.4% | 32.03 | USD 7,532,495 | |
| 2021-06-10 | 2021-06-08 | PS Planned sale |
President and CEO Executive Director |
152,643
-9.8%
32.04USD 4,890,682 |
152,643 -9.8% | 32.04 | USD 4,890,682 | |
| 2021-05-28 | 2021-05-27 | S Sale | Non-Executive Director |
78,109
-21.9%
31.94USD 2,494,801 |
78,109 -21.9% | 31.94 | USD 2,494,801 | |
| 2021-05-28 | 2021-05-27 | S Sale |
EVP, IMEA Officer |
100,000
-41.8%
31.99USD 3,199,000 |
100,000 -41.8% | 31.99 | USD 3,199,000 | |
| 2021-05-28 | 2021-05-26 | S Sale | Non-Executive Director |
150,000
-29.6%
31.89USD 4,783,500 |
150,000 -29.6% | 31.89 | USD 4,783,500 | |
| 2021-05-27 | 2021-05-26 | S Sale |
EVP, IMEA Officer |
15,000
-9.7%
31.87USD 478,050 |
15,000 -9.7% | 31.87 | USD 478,050 | |
| 2021-05-26 | 2021-05-24 | S Sale | Non-Executive Director |
157,571
-23.7%
31.57USD 4,974,516 |
157,571 -23.7% | 31.57 | USD 4,974,516 | |
| 2021-05-26 | 2021-05-24 | S Sale | Non-Executive Director |
180,000
-21.3%
31.74USD 5,713,200 |
180,000 -21.3% | 31.74 | USD 5,713,200 | |
| 2021-05-25 | 2021-05-24 | S Sale |
EVP, IMEA Officer |
9,124
-6.2%
31.75USD 289,687 |
9,124 -6.2% | 31.75 | USD 289,687 | |
| 2021-05-21 | 2021-05-20 | PS Planned sale |
EVP & General Counsel Officer |
18,488
-17.6%
31.12USD 575,347 |
18,488 -17.6% | 31.12 | USD 575,347 | |
| 2021-05-21 | 2021-05-20 | PS Planned sale |
EVP, Biopharma Production Officer |
19,603
-11.6%
31.10USD 609,653 |
19,603 -11.6% | 31.10 | USD 609,653 | |
| 2021-04-13 | 2021-04-12 | PS Planned sale |
EVP, Strategic Partners Officer |
2,505
-2.1%
32.00USD 80,160 |
2,505 -2.1% | 32.00 | USD 80,160 | |
| 2021-04-13 | 2021-04-12 | PS Planned sale |
EVP & General Counsel Officer |
100,000
-45.7%
33.21USD 3,321,000 |
100,000 -45.7% | 33.21 | USD 3,321,000 | |
| 2021-04-13 | 2021-04-12 | PS Planned sale |
EVP & General Counsel Officer |
2,895
-2.4%
31.75USD 91,916 |
2,895 -2.4% | 31.75 | USD 91,916 | |
| 2021-04-13 | 2021-04-12 | PS Planned sale |
EVP, IMEA Officer |
100,160
-39.1%
32.37USD 3,242,179 |
100,160 -39.1% | 32.37 | USD 3,242,179 | |
| 2021-03-10 | 2021-03-09 | S Sale |
EVP, Europe Officer |
10,000
-3.9%
28.21USD 282,100 |
10,000 -3.9% | 28.21 | USD 282,100 | |
| 2021-03-03 | 2021-03-02 | S Sale |
EVP & CIO Officer |
3,036
-2.0%
28.71USD 87,164 |
3,036 -2.0% | 28.71 | USD 87,164 | |
| 2021-02-26 | 2021-02-24 | PS Planned sale |
EVP, Biopharma Production Officer |
3,059
-1.7%
27.93USD 85,438 |
3,059 -1.7% | 27.93 | USD 85,438 | |
| 2021-02-23 | 2021-02-22 | PS Planned sale |
EVP, Biopharma Production Officer |
19,769
-10.1%
28.62USD 565,789 |
19,769 -10.1% | 28.62 | USD 565,789 | |
| 2021-02-08 | 2021-02-05 | S Sale |
EVP & CIO Officer |
40,000
-22.0%
29.77USD 1,190,800 |
40,000 -22.0% | 29.77 | USD 1,190,800 | |
| 2021-02-08 | 2021-02-05 | PS Planned sale |
EVP & CIO Officer |
9,468
-6.3%
29.77USD 281,862 |
9,468 -6.3% | 29.77 | USD 281,862 | |
| 2021-01-13 | 2021-01-11 | PS Planned sale |
EVP, Biopharma Production Officer |
162,248
-47.6%
30.04USD 4,873,930 |
162,248 -47.6% | 30.04 | USD 4,873,930 | |
| 2021-01-13 | 2021-01-11 | PS Planned sale |
EVP, Biopharma Production Officer |
216,332
-54.8%
30.08USD 6,507,267 |
216,332 -54.8% | 30.08 | USD 6,507,267 | |
| 2021-01-13 | 2021-01-11 | PS Planned sale |
EVP, Strategic Partners Officer |
2,505
-2.1%
30.00USD 75,150 |
2,505 -2.1% | 30.00 | USD 75,150 | |
| 2021-01-08 | 2021-01-06 | PS Planned sale |
EVP, Biopharma Production Officer |
11,509
-6.1%
27.24USD 313,505 |
11,509 -6.1% | 27.24 | USD 313,505 | |
| 2021-01-06 | 2021-01-04 | PS Planned sale |
EVP, Biopharma Production Officer |
59,418
-23.8%
27.84USD 1,654,197 |
59,418 -23.8% | 27.84 | USD 1,654,197 | |
| 2020-12-23 | 2020-12-21 | PS Planned sale |
EVP, Strategic Partners Officer |
10,020
-7.8%
27.14USD 271,943 |
10,020 -7.8% | 27.14 | USD 271,943 | |
| 2020-12-15 | 2020-12-11 | S Sale | Non-Executive Director |
14,286
-55.8%
26.68USD 381,150 |
14,286 -55.8% | 26.68 | USD 381,150 | |
| 2020-12-08 | 2020-12-07 | S Sale |
President and CEO Executive Director |
98,452
-5.1%
27.45USD 2,702,507 |
98,452 -5.1% | 27.45 | USD 2,702,507 | |
| 2020-12-08 | 2020-12-04 | S Sale |
President and CEO Executive Director |
412,188
-19.2%
27.08USD 11,162,051 |
412,188 -19.2% | 27.08 | USD 11,162,051 | |
| 2020-11-10 | 2020-11-10 | S Sale |
New Mountain Investments III, LLC Large shareholder |
36,016,093
-56.3%
24.81USD 893,490,837 |
36,016,093 -56.3% | 24.81 | USD 893,490,837 |